Pharmafile Logo

Live from Singapore: Full speed ahead – Unlock the full potential of your brand tracking

Thursday 28th June 16:00 SGT/ 16:00 CST / 17:00 JST


You know that you need to conduct regular research to track the performance of your brand. But is your brand tracking delivering the insights your stakeholders need?

Register now: https://bit.ly/2skRJf3

In this webinar, our experts Pei Li Teh and Nicole Bender Moreira will utilise knowledge and experience garnered from more than 30 years of conducting global tracking studies. They reveal how you can unlock the full potential of your brand tracking programmes.

Key areas discussed in this webinar are:

Setting up a new tracker
Make sure you get off to the right start. We show you how to translate your business needs and KPIs into a research tool which asks the right people the right questions in the right way.

Refreshing an existing tracker
Over time research can become stale. If your market environment changes, the research design may no longer be appropriate to your information needs. We reveal the signs that a tracker needs refreshing and outline the steps to take to keep it up-to-date and relevant.

Maximising the value
You need meaningful insights and actionable recommendations, sometimes very quickly as new situations arise. We explore the ways in which you can unlock their potential, such as by maximising respondent engagement, adding bolt-on qualitative questions and creating visualised outputs for stakeholders.

Question and answer session
Following the presentation there is a Q&A. 

Register now: https://bit.ly/2skRJf3

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

News: Research Partnership is listed in the Alantra Pharma Fast 50 annual report

The best performing privately-owned UK pharmaceutical businesses were revealed earlier this month with the publication of Pharma Times’ Alantra Pharma Fast 50 annual report.Read more about this report here

Event: Blending data science and market research at the Data Analytics & Insight conference

Last month Analytics Director Misti Paul attended the Data Analytics & Insight Conference. In our latest blog post she reflects on the presentations that were given and what lessons can be...

Presentation: Optimize your digital assets with UX research

US Director Liza Pliss recently presented the paper 'Optimize your digital assets with UX research' at the PMR Conference in New Jersey, USA. Don't worry if you missed it though,...

Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase

We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada. The reports consist of 30-minute quantitative online and qualitative telephone interviews with RA patients. Read more on...

Infographic: Rheumatoid arthritis (RA)

An overview of the RA biologic patientOur RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at...

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only...

Webcast: Poker face revealed: Using facial analysis to uncover deeper levels of emotional insight

In the first part of our series covering market research innovations which have value in healthcare, we demonstrate how we've been using facial analysis to delve further into respondents' reactions...

Report: Living with RA (EU, Japan and Canada) 2019 reports

Research Partnership launches new patient Living with  Rheumatoid Arthritis (EU & Japan)  2019 report.r Living with Rheumatoid Arthritis (RA) is a quantitative study conducted online amongst 390 patients diagnosed with RA in...

News: Therapy Watch launches a new wave of EU tracking in Psoriasis (PsO)

A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter. In addition from Q1...